Publications by authors named "E V Kumar"
Electrical synapses formed by Connexin 36 (Cx36) serve as a fast means for communication in the nervous systems. Only little is known about the protein complexes that constitute these synapses. In the present study, we applied different BioID strategies to screen the interactomes of Connexin 36 the major neuronal connexin and its zebrafish orthologue Cx35b in retinal neurons.
View Article and Find Full Text PDFBackground: Tranexamic acid (TXA) is an antifibrinolytic that has historically been used to treat menorrhagia and bleeding disorders. Exploration of its use in procedures has grown, and it has shown promise in its ability to achieve hemostasis with low risk to patients. Analysis of its use in Mohs micrographic surgery (MMS) is warranted due to its potential superiority to traditional methods of achieving hemostasis (direct pressure, electrocoagulation, and sutures).
View Article and Find Full Text PDFArticle Synopsis
- In follicular lymphoma (FL), doctors have trouble finding the best treatment because different patients have different types of the disease, except for one drug that helps some patients with a specific gene change.
- Researchers studied 21 patients with FL who were not getting better and were treated with two different drugs, everolimus and temsirolimus, to see how their gene changes affected treatment success.
- They found that patients who responded well to the drugs had more changes in a specific gene called CREBBP, suggesting that this gene can help predict which treatments might work better for FL patients.
Smart elevators provide substantial promise for time and energy management applications by utilizing cutting edge artificial intelligence and image processing technology. In order to improve operating efficiency, this project designs an elevator system that uses the YOLO model for object detection. Compared to traditional methods, our results show a 15% improvement in wait times and a 20% reduction in energy use.
View Article and Find Full Text PDFBackground: We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care.
Methods: A decision analytic model was completed from the healthcare payer's perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion.